Moderate

Inflammatory bowel disease in pregnancy

IBD pregnancy · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Active IBD, not its drugs, poses the greatest risk to pregnancy; most maintenance therapies are continued. The guiding principle is to conceive and remain in remission on safe, effective therapy.

Red flags

  • Flare with rectal bleeding/systemic upset
  • Dehydration or weight loss
  • Features of acute severe colitis
  • Deranged LFTs (consider obstetric causes)

Assessment

Differential diagnosis

  • IBD flare vs pregnancy-related GI symptoms
  • Hyperemesis gravidarum
  • Infective gastroenteritis / C. difficile
  • Pre-eclampsia (if deranged LFTs)
  • Intrahepatic cholestasis of pregnancy

Investigations

  • Faecal calprotectin (non-invasive flare assessment)
  • FBC, CRP, albumin, ferritin, B12, folate
  • Flexible sigmoidoscopy if essential (safe in pregnancy)
  • MRI without gadolinium if cross-sectional imaging needed (avoid CT)
  • Routine antenatal screening and nutritional review

Management

  • Ideally plan conception during steroid-free remission with optimised therapy
  • Continue maintenance 5-ASA, thiopurines, anti-TNF and vedolizumab/ustekinumab — the priority is sustained remission
  • Stop methotrexate well before conception (teratogenic) and switch to a compatible agent
  • Avoid tofacitinib and other JAK inhibitors; counsel on alternative therapy before conception
  • Continue folic acid and treat/prevent iron and B12 deficiency
  • Treat flares promptly — steroids and biologics are preferable to uncontrolled disease
  • Time the last anti-TNF dose in the third trimester per specialist advice to reduce neonatal drug levels
  • Avoid live vaccines in infants exposed to biologics in utero until ~6–12 months
  • Coordinate delivery planning — active perianal Crohn's or ileoanal pouch may favour caesarean
  • Maintain MDT care (gastroenterology, obstetrics, neonatology) throughout
  • Continue therapy postnatally; most agents are compatible with breastfeeding

Drugs & doses

Mesalazine 2–4.8 g PO daily (continue)
Azathioprine 2–2.5 mg/kg PO once daily (continue)
Infliximab/adalimumab (continue; time third-trimester dosing)
Prednisolone 40 mg PO once daily tapering (flare)
Folic acid 5 mg PO once daily

Disposition

Joint gastroenterology-obstetric MDT; pre-conception counselling clinic.

Complications & pitfalls

  • Flare causing miscarriage, preterm birth, low birth weight
  • Venous thromboembolism (pregnancy plus active IBD)
  • Nutritional deficiency
  • Neonatal immunosuppression from in-utero biologic exposure

Exam pearls

  • Active disease is more dangerous to the pregnancy than the medications used to control it
  • Stop only methotrexate and JAK inhibitors; continue thiopurines and biologics
  • Live vaccines (e.g. rotavirus, BCG) are contraindicated in biologic-exposed infants in the first months
  • VTE risk is high — ensure thromboprophylaxis during flares and admissions

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.